BioCryst Pharmaceuticals (BCRX) news
Recent news
BioCryst gets Japan nod for Orladeyo in pediatric HAE patients
AInvest Wire · 6d agoBIOCRYST PHARMACEUTICALS: Cash, cash equivalents, restricted cash and investments $354 mln at June 30, 2026
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that its cash, cash equivalents, restricted cash, and investments totaled $354 million as of June 30 . This represents an increase from the $260.8 million reported at March 31 , and reflects the company’s ongoing financial activities, including…
AInvest Wire · Aug 5, 2026BIOCRYST PHARMACEUTICALS OUTLOOK FY SALES USD 690-715 MILLION
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has demonstrated consistent growth in its flagship product, ORLADEYO, with full-year 2025 net revenue reaching $601.8 million, representing a 38% year-over-year increase . Based on this trajectory and recent updates, the company is now projecting 2026…
AInvest Wire · Aug 5, 2026BioCryst still sees FY operating expense $420M to $440M
BioCryst Pharmaceuticals reported its 2024 financial results and updated its guidance for 2025, maintaining its operating expense outlook for the year. The company expects full-year 2025 operating expenses to range between $420 million and $440 million, excluding stock-based compensation . This…
AInvest Wire · Aug 5, 2026BIOCRYST PHARMACEUTICALS - expects additional costs for discovery center closure; analysis ongoing - SEC filing
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.